THRM

Business Context and Reporting Period

Company: Gentherm Inc (THRM)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: Global leader in thermal management and pneumatic comfort technologies for automotive and medical markets. Key products include Climate Control Seats, Valve Systems, and patient temperature management systems.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Product revenues increased 11.0% ($41.1M) for the quarter and 11.1% ($80.9M) for the six months compared to the prior year periods. Growth was driven by favorable automotive volumes and foreign currency impacts (Euro, Renminbi), partially offset by unfavorable pricing and Korean Won impacts.
• Operating Expenses: Selling, general, and administrative (SG&A) expenses rose significantly by 35.6% ($14.6M) for the quarter and 39.5% ($31.4M) for the six months. This increase is primarily attributed to $12.9M (quarter) and $27.7M (six months) in merger and acquisition expenses related to the Modine Transaction.
• Restructuring: Restructuring expenses increased to $5.96M for the quarter and $12.66M for the six months, compared to $2.11M and $6.62M in the prior year periods, driven by the 2026 Plan and ongoing footprint optimization.
• Foreign Currency: Foreign currency loss improved dramatically to $0.24M (quarter) and $1.30M (six months) from losses of $17.43M and $27.73M in the prior year, due to reduced unrealized losses on intercompany receivables.
• Debt Levels: Total debt increased to $273.3M from $189.1M at year-end 2025, reflecting increased borrowings under the Revolving Credit Facility to fund operations and transaction costs.

Guidance, Outlook, and Risks

• Modine Transaction: Gentherm is in the process of combining with Modine Manufacturing Co.'s Performance Technologies business (valued at ~$1.0B). The transaction is expected to close in early Q4 2026. A $250M delayed-draw term loan facility has been secured to fund the transaction.
• IME Acquisition: Completed on July 1, 2026, the acquisition of Innovative Medical Equipment, LLC for $34.0M (net of cash/debt) to expand medical thermal therapy offerings.
• Stock Repurchase: The 2024 Stock Repurchase Program was terminated in July 2026 with $110.1M remaining. A new 2026 program was authorized for up to $400.0M. No shares were repurchased in the first half of 2026.
• Restructuring Outlook: The company expects to incur $9.0M–$9.5M in cash restructuring costs for the 2026 Plan, substantially completed by year-end 2026.
• Risks:
  • Trade Environment: Ongoing uncertainty regarding U.S. tariffs and global trade disputes, though the company believes its regional manufacturing model mitigates direct impact.
  • Warranty/Recalls: Potential material costs associated with Volkswagen and Porsche recalls regarding seat heating mats and fuel tank systems. The company has not accepted financial responsibility but cannot estimate potential costs.
  • Transaction Execution: Risks related to the closing conditions, regulatory approvals, and integration of the Modine Transaction.

Investor Verification Checklist

• Modine Transaction Closing: Verify the timeline and conditions for the Q4 2026 closing of the Modine Performance Technologies merger.
• Transaction Costs: Monitor the impact of M&A expenses on future SG&A and operating margins post-closing.
• Warranty Reserves: Track developments regarding the VW/Porsche recalls and any potential indemnification claims or cost accruals.
• Debt Covenants: Confirm continued compliance with the Credit Agreement's leverage and interest coverage ratios, especially given the increased debt load.
• Restructuring Execution: Verify the completion of the 2026 restructuring plan and the realization of expected cost savings.